Positions

Overview

  • Dr. Markert received an A.B. degree cum laude in Biochemical Sciences from Harvard University, where he also pursued graduate studies in Applied Mathematics. He then obtained his M.D. degree from Columbia University College of Physicians and Surgeons in 1988 with a simultaneous award of a Masters in Public Health, also from Columbia University. He performed his general surgery internship, as well as his neurological surgery residency, at the University of Michigan Medical Center under Dr. Julian "Buz" Hoff during the period of 1988 to 1995. During his residency, he spent 18 months in the laboratory of Dr. Robert Martuza at Massachusetts General Hospital studying the potential application of genetically-engineered herpes simplex virus as a treatment approach for malignant glioma. He then returned to the University of Michigan where he completed his Chief Residency in 1995.

    Upon completion of his residency, he became a faculty member of the Division of Neurosurgery at the University of Alabama at Birmingham. Immediately after joining the faculty, he completed an additional research program under Dr. Bernard Roizman at the University of Chicago in the area of molecular herpes virology. In April of 1996, he returned to UAB as an Assistant Professor of Neurosurgery. There, under the mentorship of Dr. Richard B. Morawetz, he prospered in the area of clinical neuro-oncologic surgery and rose through the ranks. In 2006, he was appointed Director of the Division of Neurosurgery at the University of Alabama at Birmingham. He has been fortunate to work with an extremely talented and congenial group of faculty and residents.

    On October 1, 2013, the Division of Neurosurgery was granted Departmental status by the University of Alabama School of Medicine, and Dr. Markert was named the inaugural chair of the Department of Neurosurgery.

    Dr. Markert's research interests center around novel therapies for the treatment of malignant glioma, and translating findings from the laboratory into the clinical arena. His major interest remains the use of herpes simplex virus and other viruses as oncolytic and gene therapy vectors for the treatment of malignant brain tumors and other cancers, including malignant peripheral nerve sheath tumors.

    He has been an active participant in program project grants centered at both the University of Alabama at Birmingham and the University of Chicago under the directorship of Dr. Richard Whitley, which has resulted in several new findings in this arena and he has been Co-Director of the University of Alabama at Birmingham Brain Tumor SPORE along with Dr. Yancey Gillespie.

    Dr. Markert has been extremely active in organized neurosurgery as well, holding positions in the American Association of Neurological Surgeons, Congress of Neurological Surgeons, American Academy of Neurological Surgery, and the Society of Neurological Surgeons. He has served as President of the Southern Neurosurgical Society.

    Dr. Markert's clinical interests include neurosurgical care of benign and malignant brain and spinal tumors, including open surgery and radiosurgery, as well as other aspects of general neurosurgery. He also maintains an active portfolio of clinical trials aimed at developing new approaches for the care of neurosurgical disease.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastomaCurrent Obesity Reports.  25:5799-5807. 2019
    2019 Current Approaches and Challenges in the Molecular Therapeutic Targeting of GlioblastomaWorld Neurosurgery.  129:90-100. 2019
    2019 Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistanceOncogene.  38:6159-6171. 2019
    2019 Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid TumorsMolecular Therapy - Oncolytics.  13:14-21. 2019
    2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational studyPLoS Medicine.  16. 2019
    2019 Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing RadiationHuman Gene Therapy Clinical Development.  26:1893-1905.e7. 2019
    2019 Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain TumorsWorld Neurosurgery.  122:e1592-e1598. 2019
    2019 Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesisJournal of Neuro-Oncology.  141:289-301. 2019
    2019 Current and future imaging methods for evaluating response to immunotherapy in neuro-oncologyTheranostics.  9:5085-5104. 2019
    2019 Focal Management of Large Brain Metastases and Risk of Leptomeningeal DiseaseLancet Child and Adolescent Health2019
    2019 Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceJournal of Radiology Case Reports2019
    2019 Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and ValidationAging Health2019
    2018 Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionScientific Reports.  8. 2018
    2018 The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgeryLancet Child and Adolescent Health.  3:421-430. 2018
    2018 Clinical Utility of Serum Procalcitonin Level and Infection in the Neurosurgical Intensive Care UnitWorld Neurosurgery.  112:e368-e374. 2018
    2018 Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal diseaseJournal of Clinical Neuroscience.  49:48-55. 2018
    2018 Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memoryTranslational Oncology.  11:86-93. 2018
    2018 Evaluation of multiple factors affecting normal brain dose in single-isocenter multiple target radiosurgeryJournal of Radiosurgery and SBRT.  5:131-144. 2018
    2017 Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002Molecular Therapy - Oncolytics.  7:27-36. 2017
    2017 Primary CNS Nonamyloidogenic Light Chain Deposition Disease: Case Report and Brief ReviewInternational Journal of Surgical Pathology.  25:755-760. 2017
    2017 Fractionated stereotactic radiation therapy for intact brain metastasesLancet Child and Adolescent Health.  2:564-571. 2017
    2017 Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapyFrontiers in Oncology.  7. 2017
    2017 Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human PrimatesMolecular Therapy - Oncolytics.  5:1-10. 2017
    2017 Implications of transitioning to a resident night float system in neurosurgery: Mortality, length of stay, and resident experienceJournal of Neurosurgery.  126:1269-1277. 2017
    2017 Oncolytic Virotherapy for the Treatment of Malignant GliomaNeurotherapeutics.  14:333-344. 2017
    2017 Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain TumorsHuman Gene Therapy Clinical Development.  28:7-16. 2017
    2017 Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Human Gene Therapy Clinical Development2017
    2017 Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapyCurrent Obesity Reports.  23:342-350. 2017
    2017 Beyond Alkylating Agents for Gliomas: Quo Vadimus?Journal of Health Communication.  37:175-186. 2017
    2017 Combination strategies enhance oncolytic virotherapyOncotarget.  8:34020-34021. 2017
    2016 Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcomaTranslational Oncology.  9:419-430. 2016
    2016 Interinstitutional Dosimetric Comparison Between Stereotactic Radiosurgery and Volumetric Modulated Arc Therapy Radiosurgery for Difficult Intracranial Cases.International Journal of Radiation Oncology - Biology - Physics.  96:E693. 2016
    2016 Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases.International Journal of Radiation Oncology - Biology - Physics.  96:E120-E121. 2016
    2016 Effect of resident handoffs on length of hospital and intensive care unit stay in a neurosurgical population: A cohort studyJournal of Neurosurgery.  125:222-228. 2016
    2016 Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or GliosarcomaHuman Gene Therapy Clinical Development.  27:69-78. 2016
    2016 STAT1 and NF-κB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST CellsThe Entrepreneurial Executive.  14:482-492. 2016
    2016 A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastasesLancet Child and Adolescent Health.  1:83-88. 2016
    2016 Temporal-based pericranial flaps for orbitofrontal Dural repair: A technical note and Review of the literatureInterdisciplinary Neurosurgery.  3:6-10. 2016
    2016 To infection and beyond: The multi-pronged anti-cancer mechanisms of oncolytic virusesViruses.  8. 2016
    2016 Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex virusesNeuro-Oncology.  18:227-235. 2016
    2016 Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade NeuroblastomaJournal of Immunology Research.  2016. 2016
    2015 Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CWEuropean Journal of Immunology.  29:850-858. 2015
    2015 Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15015. 2015
    2015 Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in childrenMolecular Therapy - Oncolytics.  2:15016. 2015
    2015 In Reply: Volumetric Arc Therapy (RapidArc) vs Gamma Knife Radiosurgery for Multiple Brain Metastases: Not only a Dosimetric IssueNeurosurgery.  77:E311. 2015
    2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasJournal of Neuro-Oncology.  122:585-593. 2015
    2015 Alteration of the threshold stimulus for intraoperative brain mapping via use of antiepileptic medicationsInterdisciplinary Neurosurgery.  2:16-20. 2015
    2015 Erratum: [γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia (Gene Therapy) (2015) 22: 348-355]Gene Therapy.  22:356. 2015
    2015 Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.Oncolytic Virotherapy.  4:33-38. 2015
    2015 Intracranial blastomycotic abscess mimicking malignant brain neoplasm: Successful treatment with voriconazole and surgerySurgical Neurology International.  6. 2015
    2015 Spontaneous cerebellar hemorrhage in a patient taking apixabanInterdisciplinary Neurosurgery.  2:54-56. 2015
    2015 γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxiaGene Therapy.  22:348-355. 2015
    2014 Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experienceNeuro Oncology Practice.  1:172-177. 2014
    2014 O-GLCNAC'S role in neurological disorders and its therapeutic implicationsAnnual Review of Nursing Research.  39:561-568. 2014
    2014 Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomideRadiation Oncology.  9. 2014
    2014 Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cellsPLoS ONE.  9. 2014
    2014 Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to Aotus Nonhuman PrimatesHuman Gene Therapy Clinical Development.  25:16-27. 2014
    2014 Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsPLoS ONE.  9. 2014
    2014 A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesMolecular Therapy.  22:1048-1055. 2014
    2014 Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell linesGene Therapy.  21:984-990. 2014
    2014 Comparison of plan quality and delivery time between volumetric arc therapy (rapidarc) and gamma knife radiosurgery for multiple cranial metastasesNeurosurgery.  75:409-417. 2014
    2014 Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adultsMolecular Therapy.  22:1056-1062. 2014
    2014 The history of neurosurgery at the university of Alabama at BirminghamNeurosurgery.  75:483-487. 2014
    2013 Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapyFrontiers in Oncology.  3 FEB. 2013
    2013 Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1PLoS ONE.  8. 2013
    2013 Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of NeuroblastomaPLoS ONE.  8. 2013
    2013 Viral therapy of glioblastoma multiformeProceedings of the National Academy of Sciences.  110:11672-11673. 2013
    2013 Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma MultiformePLoS ONE.  8. 2013
    2012 Human herpesviridae methods of natural killer cell evasionJournal of Perinatal Medicine.  2012. 2012
    2012 The role of early resection vs biopsy in the management of low-grade gliomasJournal of the American Medical Association.  308:1918-1919. 2012
    2012 Plan quality and treatment planning technique for single isocenter cranial radiosurgery with volumetric modulated arc therapyPractical Radiation Oncology.  2:306-313. 2012
    2012 Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous systemJournal of Neuro-Oncology.  109:513-519. 2012
    2012 Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12Journal of Virology.  86:5304-5313. 2012
    2012 Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary culturesTranslational Oncology.  5:200-207. 2012
    2012 Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases.International Journal of Breast Cancer.  2012:628697. 2012
    2012 Targeting pediatric cancer stem cells with oncolytic virotherapy.Pediatric Research.  71:500-510. 2012
    2011 Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1Gene Therapy.  18:1098-1102. 2011
    2011 Meta-analysis of hemorrhagic complications from ventriculostomy placement by neurosurgeonsNeurosurgery.  69:255-260. 2011
    2011 In reply:Neurosurgery.  68. 2011
    2011 The relationship between INR and development of hemorrhage with placement of ventriculostomyJournal of Trauma.  70:1112-1117. 2011
    2011 Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agentsMolecular Pharmaceutics.  8:44-49. 2011
    2011 Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomideThe Journal of Counselor Preparation and Supervision.  55:77-81. 2011
    2011 Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiformeJournal of Neuro-Oncology.  101:179-188. 2011
    2011 Risk factors for conversion to permanent ventricular shunt in patients receiving therapeutic ventriculostomy for traumatic brain injuryNeurosurgery.  68:85-88. 2011
    2010 Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chainJournal of Biological Chemistry.  285:39759-39767. 2010
    2010 Diffusion tensor imaging in hypertrophic olivary degenerationAmerican Literary History.  31:1729-1731. 2010
    2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastomaEuropean Journal of Immunogenetics.  67:313-319. 2010
    2010 Impact of Dose Rate on Outcomes of Gamma Knife® Radiosurgery in Patients with Face PainRadiosurgery.  7:360-365. 2010
    2009 CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental gliomaJournal of Radiology Case Reports.  16:794-805. 2009
    2009 Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastomaNeuro-Oncology.  11:357-367. 2009
    2009 Oncolytic Viral Therapy of Malignant GliomaNeurotherapeutics.  6:558-569. 2009
    2009 Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Journal of Neuro-Oncology.  95:199-209. 2009
    2009 A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.Journal of Clinical Oncology.  27:2023. 2009
    2009 Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.Journal of Clinical Oncology.  27:2042. 2009
    2009 Herpes simplex virus oncolytic therapy for pediatric malignanciesMolecular Therapy.  17:1125-1135. 2009
    2009 Cancer of the tonsil presenting as central nervous system metastasis: A case reportHead & neck surgery.  31:127-130. 2009
    2009 Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBMMolecular Therapy.  17:199-207. 2009
    2008 Hitting a moving target: Evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteriaNeurosurgical Focus.  24. 2008
    2008 Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965)Gene Therapy.  15:327. 2008
    2008 A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomasMolecular Therapy.  16:627-632. 2008
    2008 Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery AloneInternational Journal of Radiation Oncology - Biology - Physics.  70:181-186. 2008
    2007 Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic virusesGene Therapy.  14:1045-1054. 2007
    2007 Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brainJournal of NeuroVirology.  13:118-129. 2007
    2007 Necrotizing neurosarcoid: Three cases with varying presentationsInternational journal of applied science and technology.  26:59-67. 2007
    2007 Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumorsJournal of Radiology Case Reports.  14:45-56. 2007
    2006 Oncolytic HSV-1 for the treatment of brain tumoursHerpes -Cambridge-.  13:66-71. 2006
    2006 Serial passage through human glioma xenografts selects for a Δγ134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumorsJournal of Virology.  80:7308-7315. 2006
    2006 Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cellsJournal of Biological Chemistry.  281:19220-19232. 2006
    2006 Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidatesVaccine.  24:1644-1652. 2006
    2006 Bilateral metastatic renal hemangiopericytoma ten years after primary intracranial lesionInternational Brazilian Journal of Urology.  32:306-307. 2006
    2006 Dexmedetomidine as rescue drug during awake craniotomy for cortical motor mapping and tumor resectionPflügers Archiv European Journal of Physiology.  102:1556-1558. 2006
    2005 Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infectionsNeurosurgery.  57:1237-1242. 2005
    2005 Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma modelNeuro-Oncology.  7:213-224. 2005
    2005 Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12Journal of Radiology Case Reports.  12:359-368. 2005
    2004 A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingMolecular Therapy.  10:958-966. 2004
    2004 Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1Life Science Alliance.  287. 2004
    2004 Initial treatment of melanoma brain metastases using gamma knife radiosurgery: An evaluation of efficacy and toxicityBasic Research in Cardiology, Supplement.  101:825-833. 2004
    2004 Biologic warfare for a good cause: HSV-1 anti-tumor therapy.Seizure - European Journal of Epilepsy.  51:73-80. 2004
    2004 Brain metastasesJournal of Womens Health and Gender Based Medicine.  41:665-741. 2004
    2003 Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomasJournal of Neuro-Oncology.  65:203-226. 2003
    2003 Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoterGene.  313:91-101. 2003
    2003 Glioblastoma multiforme: IntroductionEnterprisers' Project.  9:148. 2003
    2003 Acid-sensing ion channels in malignant gliomasJournal of Biological Chemistry.  278:15023-15034. 2003
    2003 Glioblastoma multiforme: IntroductionEnterprisers' Project.  9:71. 2003
    2002 Protein kinase C isoform antagonism controls BNaC2 (ASIC1) functionJournal of Biological Chemistry.  277:45734-45740. 2002
    2002 The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatomaGene Therapy.  9:75-80. 2002
    2002 The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatomaGene Therapy.  9:75-80. 2002
    2001 pH Alterations "Reset" Ca2+ Sensitivity of Brain Na+ Channel 2, a Degenerin/Epithelial Na+ Ion Channel, in Planar Lipid BilayersJournal of Biological Chemistry.  276:38755-38761. 2001
    2001 Differential gene expression profiling in human brain tumorsPhysiological Genomics.  2001:21-33. 2001
    2001 Genetically engineered human herpes simplex virus in the treatment of brain tumoursHerpes -Cambridge-.  8:17-22. 2001
    2000 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene Therapy.  7:867-874. 2000
    2000 Genetically engineered HSV in the treatment of glioma: A reviewReviews in Medical Virology.  10:17-30. 2000
    2000 Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumorsProceedings of the National Academy of Sciences.  97:2208-2213. 2000
    2000 Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trialGene Therapy.  7:867-874. 2000
    1999 Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virusCurrent Obesity Reports.  5:1517-1522. 1999
    1999 Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumorsCurrent Protocols in Toxicology.  59:2055-2058. 1999
    1998 Nonsurgical management of upper cervical spine injuriesTechniques in Neurosurgery.  4:268-277. 1998
    1998 Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy.  5:121-130. 1998
    1997 Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumorsCurrent Protocols in Toxicology.  57:1502-1509. 1997
    1996 The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumorsProceedings of the National Academy of Sciences.  93:11313-11318. 1996
    1996 Use of the extreme lateral approach in the surgical treatment of an intradural ventral cervical spinal cord vascular malformation: Technical case reportNeurosurgery.  38:412-415. 1996
    1996 Spontaneous CSF fistula through a congenitally fenestrated sphenoid boneInternational Journal of Molecular Medicine.  166:952-954. 1996
    1995 Primary osseous amyloidoma causing spinal cord compressionAmerican Literary History.  16:1152-1154. 1995
    1994 CNS tumor therapy by attenuated herpes simplex viruses.Gene Therapy.  1 Suppl 1. 1994
    1993 Paroxysmal bilateral dysosmia treated by resection of the olfactory bulbsSurgical Neurology.  40:160-163. 1993
    1993 Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovirNeurosurgery.  32:597-603. 1993
    1992 Expanded spectrum of viral therapy in the treatment of nervous system tumorsJournal of Neurosurgery.  77:590-594. 1992
    1991 Experimental therapy of human glioma by means of a genetically engineered virus mutantScience.  252:854-856. 1991

    Chapter

    Year Title Altmetric
    2010 Impact of dose rate on outcomes of Gamma Knife® radiosurgery in patients with face pain.  360-365. 2010
    2007 Herpesviruses as therapeutic agents.  1341-1352. 2007

    Research Overview

  • Dr. Markert's major laboratory and clinical research interests are in the development of novel treatments for brain tumors utilizing molecular biology, viral vectors, and gene therapy. His current laboratory research focuses on engineered herpes simplex virus-1 as a vector for immunologic (e.g., cytokines and cell surface antigens) and antiangiogenic means of treating primary and metastatic central nervous system neoplasms as well as combined use with novel immunotherapeutics.
  • Principal Investigator On

  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by University of Iowa 2018 - 2020
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Wolfe Meningioma Program Project  awarded by University of California, San Francisco 2019
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Private Grant  awarded by NORTHWEST BIOTHERAPEUTICS 2015 - 2017
  • Engineered Herpes Simplex Virus for Treatment of Malignant Peripheral Nerve Sheath Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 4 - Lessons from the O.R.: Using Clinical Biologic Correlates to Inform HSV Trial Design  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2011 - 2014
  • Private Grant  awarded by SANBIO, INC. 2012 - 2014
  • Private Grant  awarded by ONCOLYTICS BIOTECH 2005 - 2011
  • Investigator On

  • Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18  awarded by Food & Drug Administration 2019 - 2022
  • Phase 1 Trial of Engineered HSV G207 in Children with Malignant Cerebellar Brain Tumors  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2019 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by NOVOCURE, INC. 2019 - 2022
  • Boosting the Systemic and in Situ CD4+ T-Cell Responses to Malignant Glioma by Oncolytic HSV Virotherapy  awarded by DOD - Department of Defense 2018 - 2021
  • Private Grant  awarded by SUNOVION PHARMACEUTICALS, INC. 2016 - 2021
  • Dual PET/Fluorescence Imaging of Glioma with an MMP-14 Activabable Peptide Probe  awarded by DOD - Department of Defense 2018 - 2020
  • Canine Immuno Neurotherapeutics  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)  awarded by Food & Drug Administration 2016 - 2020
  • Private Grant  awarded by CHAMPIONS ONCOLOGY 2018 - 2020
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2017 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2019
  • Training Program in Brain Tumor Biology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2019
  • Private Grant  awarded by NOVOCURE, INC. 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS 2016 - 2018
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Cytochrome C Oxidase in Malignant Gliomas  awarded by National Cancer Institute/NIH/DHHS 2012 - 2018
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2016 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Animal Models  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Project #1  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by GUERBET 2014 - 2016
  • Improving Oncolytic Herpes Simplex Virus for Metastatic Breast Cancer  awarded by METAVIVOR 2014 - 2015
  • Renin-Angiotensin System Polymorphisms in Pathophysiology of Ruptured Cerebral Artery Aneurysms and Development of Vasospasm After SAH  awarded by Brain Aneurysm Foundation 2012 - 2015
  • The oHSV-Mediated Immune Response: Engineering Long-Term Anti-GBM Immunity  awarded by SOUTHEASTERN BRAIN TUMOR FOUNDATION 2014 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Core A. Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 3 - Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2014 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2012 - 2014
  • Research Training Program in Surgical Oncology  awarded by National Cancer Institute/NIH/DHHS 2007 - 2012
  • Teaching Activities

  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2019) 2019
  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2018) 2018
  • STP10401 - MEDICINE AND SPIRITUALITY (Fall Term 2018) 2018
  • 80-413R - NEUROSURGERY RESEARCH (Fall Term 2018) 2018
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2016) 2016
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2013) 2013
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2012) 2012
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2012) 2012
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2011) 2011
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2010) 2010
  • 80-413R - NEUROSURGERY RESEARCH (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2009) 2009
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2008) 2008
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Fall Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • 80-422 - PEDIATRIC NEUROSURGERY (Spring Term 2007) 2007
  • Education And Training

  • Massachusetts General Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Columbia University 1988
  • Master of Public Health, Columbia University 1988
  • Bachelor of Arts in Biochemistry, Harvard University 1983
  • University of Michigan Hospitals & Health Centers, Internship 1989
  • University of Michigan Hospitals & Health Centers, Residency 1995
  • Full Name

  • James Markert